Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, GAIN THERAPEUTICS, INC reported revenue of $0M, down 60.6% year over year. Operating margin was -40328.3% and net margin -40354.3%, on a free-cash-flow margin of -34217.5% with capital expenditure at 27.8% of revenue. Every figure is computed directly from GANX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $0M | -40328.3% | -40354.3% |
| FY2022 | $0M | -12688.1% | -12555.1% |
| FY2021 | $0M | -8379.8% | -8418.9% |
| FY2020 | $0M | -12047.5% | -12387.7% |
How does GANX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.